A inositide-dependent signaling exists in the nucleus. In this review we focused to the nuclear PI-PLC signaling activity, its downstream effects and its role in haematological malignancies. PI-PLC β1 is involved in the physiological control of the cell cycle and by acting on the Cylin D3 promoter plays a crucial role in the process of C2C12 myoblast differentiation. In hematological malignancies recent studies showed that PI-PLC β1 mono-allelic deletion correlates with a higher risk of AML evolution. Moreover it has been shown that PI-PLC β1 promoter is hypermethylated in high-risk MDS patients and that the amount of PI-PLC β1 mRNA could predict the clinical response to azacitidine, a well known demethylating drug. All in all the data reviewed here pave the way to a new prognostic and therapeutic strategy in some haematological malignancies.
Cocco L, Follo MY, Faenza I, Billi AM, Ramazzotti G, Martelli AM, et al. (2010). Inositide signaling in the nucleus: From physiology to pathology.. AMSTERDAM : Elsevier [10.1016/j.advenzreg.2009.10.007].
Inositide signaling in the nucleus: From physiology to pathology.
COCCO, LUCIO ILDEBRANDO;FOLLO, MATILDE YUNG;FAENZA, IRENE;BILLI, ANNA MARIA;RAMAZZOTTI, GIULIA;MARTELLI, ALBERTO MARIA;MANZOLI, LUCIA;
2010
Abstract
A inositide-dependent signaling exists in the nucleus. In this review we focused to the nuclear PI-PLC signaling activity, its downstream effects and its role in haematological malignancies. PI-PLC β1 is involved in the physiological control of the cell cycle and by acting on the Cylin D3 promoter plays a crucial role in the process of C2C12 myoblast differentiation. In hematological malignancies recent studies showed that PI-PLC β1 mono-allelic deletion correlates with a higher risk of AML evolution. Moreover it has been shown that PI-PLC β1 promoter is hypermethylated in high-risk MDS patients and that the amount of PI-PLC β1 mRNA could predict the clinical response to azacitidine, a well known demethylating drug. All in all the data reviewed here pave the way to a new prognostic and therapeutic strategy in some haematological malignancies.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
